// App-Quantinova.ai

5566.0 : TALAPRO-1: Phase II study of talazoparib (TALA) in patients (pts) with DNA damage repair alterations (DDRm) and metastatic castration-resistant prostate cancer (mCRPC) – updated interim analysis (IA).

Researchers

Presenter

  • Johann S. De Bono

Principal Investigators

  • Niven Mehra

  • Celestia S. Higano

  • Fred Saad

  • Consuelo Buttigliero

  • Inge M. van Oort

  • Marielena Mata

  • Hsiang-Chun Chen

  • Cynthia G. Healy

  • M. Luisa Paccagnella

  • Akos Czibere

  • Karim Fizazi

Medical Centers

  • Royal Marsden Hospital and Institute of Cancer Research, London, United Kingdom

  • Department of Urology, Radboud University Medical Center, Nijmegen, Netherlands

  • Fred Hutchinson Cancer Resaerch Center, Seattle, WA

  • Centre Hospitalier de LUniversite de Montreal (CHUM), Montreal, QC, Canada

  • Department of Oncology, University of Turin, San Luigi Gonzaga Hospital, Orbassano (TO), Italy

  • Department of Urology, Radboud University Medical Center, Nijmegen, Netherlands

  • Pfizer Inc, San Diego, CA

  • Pfizer Inc, Collegeville, PA

  • Pfizer, Groton, CT

  • Pfizer Inc., Cambridge, MA

  • Institut Gustave Roussy, University of Paris Sud, Villejuif, France

Locations

  • United Kingdom

  • Netherlands

Companies

  • N/A

Study Components

Therapeutic Area

  • Genetic Disorder

  • Musculoskeletal

Disease

  • N/A

Biomarkers

  • MutL Homolog 1

  • Ataxia Telangiectasia And Rad3-Related Protein

  • Nibrin

  • Breast cancer type 1 susceptibility protein

  • checkpoint kinase 2

  • Circulating tumor cells

  • Prostate specific antigen

  • Fanconi anaemia, complementation group A

  • Partner and localizer of BRCA2

  • RAD51 Paralog C

  • Ataxia-telangiectasia mutated

Drug/Treatment

  • CB-7598

  • Enzalutamide

  • Talazoparib

  • taxane

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • NCT03148795

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved